18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.
18F-Fluciclovine (FACBC)
Amino acid transporter
Castration-resistant prostate cancer
Metabolic imaging
Tumour heterogeneity
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
25 Nov 2020
25 Nov 2020
Historique:
received:
18
06
2020
accepted:
29
10
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Prostate cancer is highly prevalent worldwide. Androgen deprivation therapy (ADT) remains the treatment of choice for incurable prostate cancer, but majority of patients develop disease recurrence following ADT. There is therefore an urgent need for early detection of treatment resistance. Isogenic androgen-responsive (CWR22Res) and castration-resistant (22Rv1) human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts. Castrated mice bearing CWR22Res and 22Rv1 orthografts mimic clinical prostate cancer following acute and chronic ADT, respectively. Both immunohistochemistry analysis of endpoint prostate tumours and longitudinal We studied in vivo
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer is highly prevalent worldwide. Androgen deprivation therapy (ADT) remains the treatment of choice for incurable prostate cancer, but majority of patients develop disease recurrence following ADT. There is therefore an urgent need for early detection of treatment resistance.
METHODS
METHODS
Isogenic androgen-responsive (CWR22Res) and castration-resistant (22Rv1) human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts. Castrated mice bearing CWR22Res and 22Rv1 orthografts mimic clinical prostate cancer following acute and chronic ADT, respectively.
RESULTS
RESULTS
Both immunohistochemistry analysis of endpoint prostate tumours and longitudinal
CONCLUSION
CONCLUSIONS
We studied in vivo
Identifiants
pubmed: 33237350
doi: 10.1186/s13550-020-00728-9
pii: 10.1186/s13550-020-00728-9
pmc: PMC7688773
doi:
Types de publication
Journal Article
Langues
eng
Pagination
143Subventions
Organisme : Medical Research Council
ID : MR/L017997/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22904
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A25006
Pays : United Kingdom
Références
Life Sci Alliance. 2020 Oct 8;3(12):
pubmed: 33033111
Cancer Res. 2011 Dec 15;71(24):7525-36
pubmed: 22007000
Nucl Med Biol. 2013 Jul;40(5):670-5
pubmed: 23647854
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):316-324
pubmed: 32068113
EJNMMI Res. 2019 May 31;9(1):50
pubmed: 31152256
Theranostics. 2012;2(3):318-30
pubmed: 22448198
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Urol Int. 2014;92(2):242-5
pubmed: 24334968
Clin Genitourin Cancer. 2014 Apr;12(2):106-10
pubmed: 24135632
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Clin Nucl Med. 2019 Oct;44(10):e566-e573
pubmed: 31283605
J Nucl Med. 2011 May;52(5):822-9
pubmed: 21536930
J Urol. 2017 Mar;197(3 Pt 1):676-683
pubmed: 27746282
Clin Nucl Med. 2015 Aug;40(8):e386-91
pubmed: 26053708
Nucl Med Biol. 2015 Nov;42(11):887-92
pubmed: 26278491
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29540470
Mol Imaging Biol. 2014 Dec;16(6):756-64
pubmed: 24943499
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10
pubmed: 26960562
J Pathol. 2015 Jul;236(3):278-89
pubmed: 25693838
J Clin Invest. 2013 Mar;123(3):1157-75
pubmed: 23434594
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83
pubmed: 27091135
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Nucl Med Biol. 2012 Jan;39(1):109-19
pubmed: 21958853